Effect of permethrin 2/5% with Tea tree oil in rosacea

Effects of permethrin 2.5% with tea tree oil topical gel in comparison with placebo on Demodex density and clinical features in rosacea patients: a double-blind, randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140304016837N4

Enrollment

Registered

2019-01-14

Start date

2017-04-04

Completion date

Unknown

Last updated

2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea. Rosacea

Interventions

Intervention 1: Each patient randomly applied the permethrin 2.5% with Tea tree oil gel on the clean skin of one side of the face twice daily for 12 weeks. Intervention 2: Control group: Each patient

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with papulopustular Rosacea At least 5 mites per square centimeter in the facial biopsy samples of both left and right sides At least 18 years old, regardless of gender

Exclusion criteria

Exclusion criteria: Rosacea patients with less than 5 mites per square centimeter in the facial biopsy samples of one or both left and right sides Patients with different types of skin cancers Patients with severe skin infections; Patients with severe burnings Sensitivity to permethrin Pregnant women Breastfeeding women

Design outcomes

Primary

Measure	Time frame
Density of Demodex mites per centimeter squared of the facial surface on the left and right sides. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation for both sides of the face. Method of measurement: Standard skin surface biopsy.	—

Secondary

Measure	Time frame
Transient erythema,. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation of the study. Method of measurement: The clinical presentations of both sides of the face were assessed by photography and the clinical criteria of the National Rosacea Society Scorecard.;Nontransient erythema. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation of the study. Method of measurement: The clinical presentations of both sides of the face were assessed by photography and the clinical criteria of the National Rosacea Society Scorecard.;Papules and pustules. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation of the study. Method of measurement: The clinical presentations of both sides of the face were assessed by photography and the clinical criteria of the National Rosacea Society Scorecard.;Telangiectasia. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation of the study. Method of measurement: The clinical presentations of both sides of the face were assessed by photography and the clinical criteria of the National Rosacea Society Scorecard.	—

Measure

Time frame

Transient erythema,. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation of the study. Method of measurement: The clinical presentations of both sides of the face were assessed by photography and the clinical criteria of the National Rosacea Society Scorecard.;Nontransient erythema. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation of the study. Method of measurement: The clinical presentations of both sides of the face were assessed by photography and the clinical criteria of the National Rosacea Society Scorecard.;Papules and pustules. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation of the study. Method of measurement: The clinical presentations of both sides of the face were assessed by photography and the clinical criteria of the National Rosacea Society Scorecard.;Telangiectasia. Timepoint: Baseline and the 2nd, 5th, 8th, and 12th weeks after the initiation of the study. Method of measurement: The clinical presentations of both sides of the face were assessed by photography and the clinical criteria of the National Rosacea Society Scorecard.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Elnaz Ebneyamin

Islamic Azad University

Elnazebneyamin@yahoo.com+98 21 8821 0291

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026